...Jun Luo; Zehui Rao; Kun Zhou; Kun Liu; Runfu Cao; Kaihong Wang Introduction: Degarelix and relugolix are two GnRH antagonists approved by the FDA for androgen deprivation therapy in the treatment of prostate cancer. However, differences in their safety profiles and the characteristics of specific...

...Moustafa Elleisy; Irene Resch; Ozan Yurdakul; Nicolai A. Hübner; Shahrokh Shariat Introduction: Abiraterone acetate is an inhibitor of androgen biosynthesis and is approved as a treatment for metastatic castration-resistant and metastatic castration-sensitive prostate cancer. Neither relugolix nor...